Furthermore, median survival time from first distant metastasis varied a lot among different molecular subtypes of breast cancer, with luminal A patients of 2.2 years, luminal B patients of 1.6 years, HER2 enriched patients of 0.7 year and basal-like patients of 0.5 year [33]. Here, ERBB2 is linked to breast cancer.